Engineering of VCAM-1-targeted Nanostructured Lipid Carriers for Delivery of Melatonin Against Acute Lung Injury Through SIRT1/NLRP3 Mediated Pyroptosis Signaling Pathway

Jian-Bo Jin,Jing Li,Hong-Bo Wang,Jing-Bo Hu,Chun-Lin Yang
DOI: https://doi.org/10.1016/j.ijbiomac.2024.130637
IF: 8.2
2024-01-01
International Journal of Biological Macromolecules
Abstract:Acute lung injury (ALI) is a prevalent and critical condition in clinical practice. Although certain pharmacological interventions have demonstrated benefits in preclinical studies, none have been proven entirely effective thus far. Therefore, the development of more efficient treatment strategies for ALI is imperative. In this study, we prepared nanostructured lipid carriers (NLCs) conjugated with anti-VCAM-1 antibodies to encapsulate melatonin (MLT), resulting in VCAM/MLT NLCs. This approach aimed to enhance the distribution of melatonin in lung vascular endothelial cells. The VCAM/MLT NLCs had an average diameter of 364 nm, high drug loading content, and a sustained drug release profile. Notably, the NLCs conjugated with anti-VCAM-1 antibodies demonstrated more specific cellular delivery mediated by the VCAM-1 receptors, increased cellular internalization, and enhanced accumulation in lung tissues. Treatment with VCAM/MLT NLCs effectively alleviated pulmonary inflammation by activating NLRP3 inflammasome-dependent pyroptosis through up-regulation of Sirtuin 1. Our findings suggest that VCAM/MLT NLCs demonstrate remarkable therapeutic effects on ALI in both in vitro and in vivo settings, making them a promising and efficient treatment strategy for ALI.
What problem does this paper attempt to address?